Unaudited Forward-Looking Statements Regarding Business Outlook | ||||
|
|
| ||
Business Outlook |
|
Three Months Ending April 1, 2017 | ||
|
|
High |
|
Low |
Estimated GAAP diluted earnings per share |
|
$0.27 |
|
$0.21 |
|
|
|
|
|
Estimated non-GAAP charges |
|
0.36 |
|
0.36 |
|
|
|
|
|
Estimated non-GAAP diluted earnings per share |
|
$0.63 |
|
$0.57 |
Silicon Laboratories Inc.
| |||
| |||
|
December 31,
|
|
January 2,
|
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ 141,106 |
|
$ 114,085 |
Short-term investments |
153,961 |
|
128,901 |
Accounts receivable, net |
74,401 |
|
73,601 |
Inventories |
59,578 |
|
53,895 |
Prepaid expenses and other current assets |
61,805 |
|
52,658 |
Total current assets |
490,851 |
|
423,140 |
Long-term investments |
5,196 |
|
7,126 |
Property and equipment, net |
129,559 |
|
131,132 |
Goodwill |
276,130 |
|
272,722 |
Other intangible assets, net |
103,565 |
|
121,354 |
Other assets, net |
76,543 |
|
55,989 |
Total assets |
$1,081,844 |
|
$1,011,463 |
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ 39,577 |
|
$ 42,127 |
Current portion of long-term debt |
-- |
|
10,000 |
Accrued expenses |
50,100 |
|
52,131 |
Deferred income on shipments to distributors |
45,568 |
|
35,448 |
Income taxes |
4,450 |
|
2,615 |
Total current liabilities |
139,695 |
|
142,321 |
Long-term debt |
72,500 |
|
67,500 |
Other non-current liabilities |
42,691 |
|
40,528 |
Total liabilities |
254,886 |
|
250,349 |
Commitments and contingencies |
|
|
|
Stockholders' equity: |
|
|
|
Preferred stock – $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding |
-- |
|
-- |
Common stock – $0.0001 par value; 250,000 shares authorized; 41,889 and 41,727 shares issued and outstanding at December 31, 2016 and January 2, 2016, respectively |
4 |
|
4 |
Additional paid-in capital |
24,463 |
|
13,868 |
Retained earnings |
801,999 |
|
747,749 |
Accumulated other comprehensive income (loss) |
492 |
|
(507) |
Total stockholders' equity |
826,958 |
|
761,114 |
Total liabilities and stockholders' equity |
$1,081,844 |
|
$1,011,463 |
Silicon Laboratories Inc.
| |||
| |||
|
Year Ended | ||
|
December 31,
|
|
January 2,
|
Operating Activities |
|
|
|
Net income |
$ 61,494 |
|
$ 29,586 |
Adjustments to reconcile net income to cash provided by operating activities: |
|
|
|
Depreciation of property and equipment |
13,216 |
|
12,517 |
Amortization of other intangible assets and other assets |
27,715 |
|
29,131 |
Stock-based compensation expense |
39,628 |
|
42,791 |
Income tax benefit (shortfall) from stock-based awards |
(1,099) |
|
469 |
Excess income tax benefit from stock-based awards |
(572) |
|
(2,497) |
Deferred income taxes |
(4,087) |
|
(2,136) |
Changes in operating assets and liabilities: |
|
|
|
Accounts receivable |
46 |
|
1,702 |
Inventories |
(6,093) |
|
2,093 |
Prepaid expenses and other assets |
(3,568) |
|
(870) |
Accounts payable |
263 |
|
6,662 |
Accrued expenses |
5,919 |
|
1,682 |
Deferred income on shipments to distributors |
9,713 |
|
(5,298) |
Income taxes |
(3,040) |
|
776 |
Other non-current liabilities |
(10,625) |
|
(11,161) |
Net cash provided by operating activities |
128,910 |
|
105,447 |
|
|
|
|
Investing Activities |
|
|
|
Purchases of available-for-sale investments |
(185,231) |
|
(107,366) |
Sales and maturities of available-for-sale investments |
161,921 |
|
171,831 |
Purchases of property and equipment |
(10,927) |
|
(11,268) |
Purchases of other assets |
(8,801) |
|
(6,399) |
Acquisitions of businesses, net of cash acquired |
(6,546) |
|
(96,112) |
Net cash used in investing activities |
(49,584) |
|
(49,314) |
|
|
|
|
Financing Activities |
|
|
|
Proceeds from issuance of long-term debt, net |
-- |
|
81,238 |
Payments on debt |
(5,000) |
|
(94,706) |
Repurchases of common stock |
(40,543) |
|
(71,448) |
Payment of taxes withheld for vested stock awards |
(11,133) |
|
(13,869) |
Proceeds from the issuance of common stock |
13,299 |
|
16,998 |
Excess income tax benefit from stock-based awards |
572 |
|
2,497 |
Payment of acquisition-related contingent consideration |
(9,500) |
|
(4,464) |
Net cash used in financing activities |
(52,305) |
|
(83,754) |
|
|
|
|
Increase (decrease) in cash and cash equivalents |
27,021 |
|
(27,621) |
Cash and cash equivalents at beginning of period |
114,085 |
|
141,706 |
Cash and cash equivalents at end of period |
$141,106 |
|
$114,085 |
To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/silicon-labs-announces-record-revenue-for-fourth-quarter-and-full-year-2016-300400039.html
SOURCE Silicon Labs
Contact: |
Silicon Labs
Web: http://www.silabs.com |